LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 142

Search options

  1. Article: [Ⅲ.Estrogen Receptor and MicroRNA].

    Toyama, Tatsuya / Wanifuchi-Endo, Yumi

    Gan to kagaku ryoho. Cancer & chemotherapy

    2019  Volume 46, Issue 12, Page(s) 1844–1847

    MeSH term(s) Breast Neoplasms ; Cell Line, Tumor ; Estrogens ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; MicroRNAs ; Receptors, Estrogen
    Chemical Substances Estrogens ; MicroRNAs ; Receptors, Estrogen
    Language Japanese
    Publishing date 2019-12-06
    Publishing country Japan
    Document type Journal Article
    ZDB-ID 604842-0
    ISSN 0385-0684
    ISSN 0385-0684
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: [MicroRNA-210 in breast cancer].

    Toyama, Tatsuya

    Nihon rinsho. Japanese journal of clinical medicine

    2012  Volume 70 Suppl 7, Page(s) 170–173

    MeSH term(s) Breast Neoplasms/chemistry ; Cell Hypoxia ; Female ; Humans ; MicroRNAs/analysis ; MicroRNAs/genetics ; Prognosis
    Chemical Substances MIRN210 microRNA, human ; MicroRNAs
    Language Japanese
    Publishing date 2012-09
    Publishing country Japan
    Document type Journal Article
    ZDB-ID 390903-7
    ISSN 0047-1852
    ISSN 0047-1852
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Ruptured breast implant removal because of patient anxiety in the absence of breast implant-associated anaplastic large cell lymphoma.

    Takahashi, Hitomi / Sato, Hideyoshi / Tsunekawa, Yukiyo / Fujioka, Urara / Wanifuchi-Endo, Yumi / Toyama, Tatsuya / Toriyama, Kazuhiro

    Nagoya journal of medical science

    2023  Volume 85, Issue 4, Page(s) 852–856

    Abstract: Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) has been regarded as a long-term problem after silicone breast implantations. We report a case in which BIA-ALCL and breast cancer were not detected preoperatively, with subsequent ... ...

    Abstract Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) has been regarded as a long-term problem after silicone breast implantations. We report a case in which BIA-ALCL and breast cancer were not detected preoperatively, with subsequent removal of a ruptured breast implant. A 52-year-old woman had silicone breast implants on both sides for breast augmentation 15 years ago. Right axillary lymphadenopathy and intracapsular ruptures were noted by magnetic resonance imaging. Right axillary lymph node biopsy was performed at our department of breast surgery. Flow cytometry for BIA-ALCL was also performed using the exudate around the implant. The results were negative for breast cancer and BIA-ALCL. However, taking into consideration exacerbation of breast implant rupture and the patient's anxiety about BIA-ALCL, ruptured bilateral implants were removed by total capsulectomy. The postoperative course was uneventful 1 year after the operation, and her anxiety was dispelled despite her breast deformity. Appropriate explantation and periodic examination may be required to prevent excessive anxiety.
    MeSH term(s) Humans ; Female ; Middle Aged ; Breast Implants/adverse effects ; Breast Implantation/adverse effects ; Breast Implantation/methods ; Lymphoma, Large-Cell, Anaplastic/etiology ; Lymphoma, Large-Cell, Anaplastic/surgery ; Mammaplasty/adverse effects ; Breast Neoplasms/surgery ; Breast Neoplasms/pathology ; Anxiety/etiology ; Silicones
    Chemical Substances Silicones
    Language English
    Publishing date 2023-12-18
    Publishing country Japan
    Document type Case Reports
    ZDB-ID 193148-9
    ISSN 2186-3326 ; 0027-7622
    ISSN (online) 2186-3326
    ISSN 0027-7622
    DOI 10.18999/nagjms.85.4.852
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Three-compartment spectral diffusion analysis for breast cancer magnetic resonance imaging.

    Ogawa, Masaki / Kan, Hirohito / Urano, Misugi / Kawai, Tatsuya / Nakajima, Haruna / Murai, Kazuma / Miyaji, Hirotaka / Toyama, Tatsuya / Hiwatashi, Akio

    Magnetic resonance imaging

    2023  Volume 103, Page(s) 179–184

    Abstract: Rationale and objectives: To examine the diagnostic performance of a three-compartment diffusion model with the fixed cut-off diffusion coefficient (D) using magnetic resonance spectral diffusion analysis for differentiating between invasive ductal ... ...

    Abstract Rationale and objectives: To examine the diagnostic performance of a three-compartment diffusion model with the fixed cut-off diffusion coefficient (D) using magnetic resonance spectral diffusion analysis for differentiating between invasive ductal carcinoma (IDC) and ductal carcinoma in situ (DCIS) and compare the conventional apparent D (ADC), and mean kurtosis (MK), with the tissue D (D
    Patients and methods: This retrospective study included women who underwent breast MRI with eight b-value diffusion-weighted imaging between February 2019 and March 2022. Spectral diffusion analysis was performed; very-slow, cellular, and perfusion compartments were defined using cut-off Ds of 0.1 × 10
    Results: Histologically confirmed 132 ICD and 62 DCIS (age range 31-87 [53 ± 11] years) were evaluated. The areas under the curve (AUCs) for ADC, MK, D
    Conclusion: Three-compartment model analysis using the diffusion spectrum accurately differentiated IDC from DCIS; however, it was not superior to ADC and D
    MeSH term(s) Humans ; Female ; Adult ; Middle Aged ; Aged ; Aged, 80 and over ; Breast Neoplasms/diagnostic imaging ; Breast Neoplasms/pathology ; Carcinoma, Intraductal, Noninfiltrating ; Retrospective Studies ; Magnetic Resonance Imaging ; Diffusion Magnetic Resonance Imaging/methods ; Motion
    Language English
    Publishing date 2023-05-11
    Publishing country Netherlands
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 604885-7
    ISSN 1873-5894 ; 0730-725X
    ISSN (online) 1873-5894
    ISSN 0730-725X
    DOI 10.1016/j.mri.2023.04.006
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Characterizing user demographics in posts related to breast, lung and colon cancer on Japanese twitter (X).

    Kusudo, Maho / Terada, Mitsuo / Kureyama, Nari / Wanifuchi-Endo, Yumi / Fujita, Takashi / Asano, Tomoko / Kato, Akiko / Mori, Makiko / Horisawa, Nanae / Toyama, Tatsuya

    Scientific reports

    2024  Volume 14, Issue 1, Page(s) 6485

    Abstract: Various cancer-related information is spreading on social media. Our study aimed to examine the account types associated with cancer-related tweets (currently known as posts) on Twitter (currently known as X) in Japan, specifically focusing on breast, ... ...

    Abstract Various cancer-related information is spreading on social media. Our study aimed to examine the account types associated with cancer-related tweets (currently known as posts) on Twitter (currently known as X) in Japan, specifically focusing on breast, lung, and colon cancer. Using the Twitter application programming interface, we collected tweets containing keywords of the three cancers type in August-September 2022. The accounts were categorized into seven types: Survivor, Patient's family, Healthcare provider, Public organization, Private organization, News, and Other according to account name and texts. We analyzed the sources of the top 50 most liked and retweeted tweets. Out of 7753 identified tweets, breast cancer represented the majority (62.8%), followed by lung cancer (20.8%) and colon cancer (16.3%). Tweets came from 4976 accounts. Account types varied depending on the cancer type, with breast cancer topics more frequently from Survivor (16.0%) and lung cancer from Patient's family (16.3%). Healthcare provider and Public organization had minimal representation across three cancer types. The trends in the top 50 tweets mirrored the distribution of accounts for each cancer type. Breast cancer-related tweets had the highest frequency. There were few from public organizations. These findings emphasize the need to consider the characteristics of cancer-related information sources when sharing and gathering information on social media.
    MeSH term(s) Humans ; Female ; Social Media ; Japan/epidemiology ; Colonic Neoplasms/epidemiology ; Breast Neoplasms/epidemiology ; Lung Neoplasms/epidemiology ; Lung ; Demography
    Language English
    Publishing date 2024-03-18
    Publishing country England
    Document type Journal Article
    ZDB-ID 2615211-3
    ISSN 2045-2322 ; 2045-2322
    ISSN (online) 2045-2322
    ISSN 2045-2322
    DOI 10.1038/s41598-024-56679-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis.

    Shimoi, Tatsunori / Sagara, Yasuaki / Hara, Fumikata / Toyama, Tatsuya / Iwata, Hiroji

    Breast cancer (Tokyo, Japan)

    2020  Volume 27, Issue 3, Page(s) 340–346

    Abstract: Background: In establishing the 2018 Breast Cancer Practice Guidelines of the Japan Breast Cancer Society, we explored the optimal first-line endocrine therapy for advanced postmenopausal hormone receptor-positive breast cancer.: Methods: We ... ...

    Abstract Background: In establishing the 2018 Breast Cancer Practice Guidelines of the Japan Breast Cancer Society, we explored the optimal first-line endocrine therapy for advanced postmenopausal hormone receptor-positive breast cancer.
    Methods: We performed a systematic review of relevant reports from randomized-controlled studies published prior to November 2016 found using medical journal search engines. The main outcomes which we evaluated were progression-free survival (PFS), objective response rate (ORR), disease control rate (CBR), and toxicity.
    Results: Four controlled trials comparing aromatase inhibitors (AI) and cyclin-dependent kinase (CDK)4/6 inhibitor combination therapy to AI monotherapy, and two controlled trials comparing anastrozole to fulvestrant 500 mg were analyzed. AI/CDK4/6 inhibitor combination therapy significantly improved PFS (Risk Ratio: 0.67, 95%CI 0.60-0.73), increased ORR (Risk Difference: 0.11, 95% CI 0.07-0.16), and increased CBR (Risk Difference: 0.11, 95% CI 0.07-0.15), compared with AI monotherapy. Patients who received this combination therapy had a higher grade ≥ 3 adverse event rate more than those who received AI monotherapy (Risk Difference: 43%, 95%CI: 0.39-0.47). Fulvestrant 500 mg alone significantly improved PFS (risk ratio: 0.85, 95%CI 0.72-0.98), but ORR and CBR were similar to those of anastrozole alone.
    Conclusion: In the first-line treatment for advanced postmenopausal hormone receptor-positive breast cancer, a combination therapy of CDK4/6 inhibitors and AI showed significant improvement of PFS, ORR, and CBR but with significant increased toxicities compared with AI alone. Fulvestrant 500 mg monotherapy significantly prolonged PFS compared with AI monotherapy. We must wait for the results of the studies with longer follow-up period.
    MeSH term(s) Aromatase Inhibitors/therapeutic use ; Biomarkers, Tumor/metabolism ; Breast Neoplasms/drug therapy ; Breast Neoplasms/metabolism ; Breast Neoplasms/pathology ; Female ; Humans ; Postmenopause ; Prognosis ; Receptor, ErbB-2/metabolism ; Receptors, Estrogen/metabolism ; Receptors, Progesterone/metabolism
    Chemical Substances Aromatase Inhibitors ; Biomarkers, Tumor ; Receptors, Estrogen ; Receptors, Progesterone ; ERBB2 protein, human (EC 2.7.10.1) ; Receptor, ErbB-2 (EC 2.7.10.1)
    Language English
    Publishing date 2020-02-11
    Publishing country Japan
    Document type Journal Article ; Meta-Analysis ; Systematic Review
    ZDB-ID 2052429-8
    ISSN 1880-4233 ; 1340-6868
    ISSN (online) 1880-4233
    ISSN 1340-6868
    DOI 10.1007/s12282-020-01054-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Risks and benefits of bevacizumab combined with chemotherapy for advanced or metastatic breast cancer: a meta-analysis of randomized controlled trials.

    Miyashita, Minoru / Hattori, Masaya / Takano, Toshimi / Toyama, Tatsuya / Iwata, Hiroji

    Breast cancer (Tokyo, Japan)

    2020  Volume 27, Issue 3, Page(s) 347–354

    Abstract: Background: The combination of bevacizumab and chemotherapy has greatly improved progression-free survival (PFS) and objective response rate (ORR) in HER2-negative metastatic breast cancer in many pivotal trials. However, risk-benefit balance related to ...

    Abstract Background: The combination of bevacizumab and chemotherapy has greatly improved progression-free survival (PFS) and objective response rate (ORR) in HER2-negative metastatic breast cancer in many pivotal trials. However, risk-benefit balance related to bevacizumab addition could not be confirmed because of a lack of overall survival (OS) improvement. Therefore, we conducted a meta-analysis to evaluate multiple endpoints pertaining to bevacizumab use in metastatic breast cancer (MBC) treatment.
    Methods: We searched PubMed and Cochrane Library databases and included seven studies in our meta-analysis in which bevacizumab combined with chemotherapy was compared with chemotherapy alone in MBC.
    Results: Compared to the chemotherapy-alone group, the combination treatment group had significantly improved PFS [hazard ratio (HR): 0.72, 95% CI 0.67-0.77, P < 0.00001]. Furthermore, bevacizumab addition did not significantly improve OS (HR: 0.95, 95% CI 0.87-1.03, P = 0.22). The ORRs in the combination treatment and chemotherapy-alone groups were 42% and 32%, respectively (HR: 1.47, 95% CI 1.26-1.71, P < 0.00001). Bevacizumab addition significantly increased the incidence of therapy discontinuation due to toxicity and toxicity of grade 3 or higher (HR: 1.43, 95% CI 1.06-1.93, P = 0.02, HR: 1.43; 95% CI 1.25-1.64, P < 0.00001, respectively). A qualitative systematic review of two randomized controlled trials indicated no significant differences in quality of life from baseline between the two groups.
    Conclusions: Compared to chemotherapy alone, bevacizumab combined with chemotherapy significantly improved PFS in the HER2-negative MBC patients. However, the lack of a significant OS difference remained.
    MeSH term(s) Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bevacizumab/therapeutic use ; Breast Neoplasms/drug therapy ; Breast Neoplasms/secondary ; Female ; Humans ; Prognosis ; Quality of Life ; Randomized Controlled Trials as Topic ; Risk Assessment/methods
    Chemical Substances Bevacizumab (2S9ZZM9Q9V)
    Language English
    Publishing date 2020-01-23
    Publishing country Japan
    Document type Journal Article ; Meta-Analysis
    ZDB-ID 2052429-8
    ISSN 1880-4233 ; 1340-6868
    ISSN (online) 1880-4233
    ISSN 1340-6868
    DOI 10.1007/s12282-020-01052-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment.

    Yamamoto, Yutaka / Yamauchi, Chikako / Toyama, Tatsuya / Nagai, Shigenori / Sakai, Takehiko / Kutomi, Goro / Yoshimura, Michio / Kawai, Masaaki / Ohtani, Shoichiro / Kubota, Kazunori / Nakashima, Kazutaka / Honma, Naoko / Yoshida, Masayuki / Tokunaga, Eriko / Taira, Naruto / Iwata, Hiroji / Saji, Shigehira

    Breast cancer (Tokyo, Japan)

    2024  Volume 31, Issue 3, Page(s) 340–346

    Abstract: The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition was published in June 2022. The guidelines were prepared while conforming as much as possible to the "Minds Manual for Guideline Development 2020 ver. 3.0." ... ...

    Abstract The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition was published in June 2022. The guidelines were prepared while conforming as much as possible to the "Minds Manual for Guideline Development 2020 ver. 3.0." edited by the Minds Manual Development Committee of the Japan Council for Quality Health Care in 2021. In addition, a survey of Japanese Breast Cancer Society members on the 2018 edition of the guidelines was conducted from February 19 to March 4, 2021. Based on the responses from over 600 members, original innovations were made to make the guidelines more user-friendly. The 2018 edition of the guidelines was developed to provide support tools for physicians and patients to utilize shared decision-making. The 2022 guidelines consist of two volumes: (1) an "Epidemiology and Diagnosis" section covering "Screening and Diagnosis", "Radiological diagnosis", and "Pathological diagnosis", and (2) a "Treatment" section covering "Surgical therapy", "Radiation therapy", and "Systemic therapy". We believe that this concise summary of the guidelines will be useful to physicians and researchers in Japan and overseas.
    MeSH term(s) Humans ; Breast Neoplasms/therapy ; Breast Neoplasms/diagnosis ; Breast Neoplasms/pathology ; Female ; Japan ; Societies, Medical ; Practice Guidelines as Topic ; Medical Oncology/standards ; East Asian People
    Language English
    Publishing date 2024-04-03
    Publishing country Japan
    Document type Journal Article ; Practice Guideline
    ZDB-ID 2052429-8
    ISSN 1880-4233 ; 1340-6868
    ISSN (online) 1880-4233
    ISSN 1340-6868
    DOI 10.1007/s12282-024-01566-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Correction: The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment.

    Yamamoto, Yutaka / Yamauchi, Chikako / Toyama, Tatsuya / Nagai, Shigenori / Sakai, Takehiko / Kutomi, Goro / Yoshimura, Michio / Kawai, Masaaki / Ohtani, Shoichiro / Kubota, Kazunori / Nakashima, Kazutaka / Honma, Naoko / Yoshida, Masayuki / Tokunaga, Eriko / Taira, Naruto / Iwata, Hiroji / Saji, Shigehira

    Breast cancer (Tokyo, Japan)

    2024  

    Language English
    Publishing date 2024-05-12
    Publishing country Japan
    Document type Published Erratum
    ZDB-ID 2052429-8
    ISSN 1880-4233 ; 1340-6868
    ISSN (online) 1880-4233
    ISSN 1340-6868
    DOI 10.1007/s12282-024-01589-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Fact-Checking Cancer Information on Social Media in Japan: Retrospective Study Using Twitter.

    Kureyama, Nari / Terada, Mitsuo / Kusudo, Maho / Nozawa, Kazuki / Wanifuchi-Endo, Yumi / Fujita, Takashi / Asano, Tomoko / Kato, Akiko / Mori, Makiko / Horisawa, Nanae / Toyama, Tatsuya

    JMIR formative research

    2023  Volume 7, Page(s) e49452

    Abstract: Background: The widespread use of social media has made it easier for patients to access cancer information. However, a large amount of misinformation and harmful information that could negatively impact patients' decision-making is also disseminated on ...

    Abstract Background: The widespread use of social media has made it easier for patients to access cancer information. However, a large amount of misinformation and harmful information that could negatively impact patients' decision-making is also disseminated on social media platforms.
    Objective: We aimed to determine the actual amount of misinformation and harmful information as well as trends in the dissemination of cancer-related information on Twitter, a representative social media platform. Our findings can support decision-making among Japanese patients with cancer.
    Methods: Using the Twitter app programming interface, we extracted tweets containing the term "cancer" in Japanese that were posted between August and September of 2022. The eligibility criteria were the cancer-related tweets with the following information: (1) reference to the occurrence or prognosis of cancer, (2) recommendation or nonrecommendation of actions, (3) reference to the course of cancer treatment or adverse events, (4) results of cancer research, and (5) other cancer-related knowledge and information. Finally, we selected the top 100 tweets with the highest number of "likes." For each tweet, 2 independent reviewers evaluated whether the information was factual or misinformation, and whether it was harmful or safe with the reasons for the decisions on the misinformation and harmful tweets. Additionally, we examined the frequency of information dissemination using the number of retweets for the top 100 tweets and investigated trends in the dissemination of information.
    Results: The extracted tweets totaled 69,875. Of the top 100 cancer-related tweets with the most "likes" that met the eligibility criteria, 44 (44%) contained misinformation, 31 (31%) contained harmful information, and 30 (30%) contained both misinformation and harmful information. Misinformation was described as Unproven (29/94, 40.4%), Disproven (19/94, 20.2%), Inappropriate application (4/94, 4.3%), Strength of evidence mischaracterized (14/94, 14.9%), Misleading (18/94, 18%), and Other misinformation (1/94, 1.1%). Harmful action was described as Harmful action (9/59, 15.2%), Harmful inaction (43/59, 72.9%), Harmful interactions (3/59, 5.1%), Economic harm (3/59, 5.1%), and Other harmful information (1/59, 1.7%). Harmful information was liked more often than safe information (median 95, IQR 43-1919 vs 75.0 IQR 43-10,747; P=.04). The median number of retweets for the leading 100 tweets was 13.5 (IQR 0-2197). Misinformation was retweeted significantly more often than factual information (median 29.0, IQR 0-502 vs 7.5, IQR 0-2197; P=.01); harmful information was also retweeted significantly more often than safe information (median 35.0, IQR 0-502 vs 8.0, IQR 0-2197; P=.002).
    Conclusions: It is evident that there is a prevalence of misinformation and harmful information related to cancer on Twitter in Japan and it is crucial to increase health literacy and awareness regarding this issue. Furthermore, we believe that it is important for government agencies and health care professionals to continue providing accurate medical information to support patients and their families in making informed decisions.
    Language English
    Publishing date 2023-09-06
    Publishing country Canada
    Document type Journal Article
    ISSN 2561-326X
    ISSN (online) 2561-326X
    DOI 10.2196/49452
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top